University of Wollongong

Research Online
Faculty of Science - Papers (Archive)

Faculty of Science, Medicine and Health

1-1-2010

Carboxymethylated-k-casein: A convenient tool for the identification of
polyphenolic inhibitors of amyloid fibril formation
John A. Carver
Peter J. Duggan
Heath Ecroyd
University of Wollongong, heathe@uow.edu.au

Yanqin Liu
University of Adelaide

Adam G. Meyer

See next page for additional authors

Follow this and additional works at: https://ro.uow.edu.au/scipapers
Part of the Life Sciences Commons, Physical Sciences and Mathematics Commons, and the Social
and Behavioral Sciences Commons

Recommended Citation
Carver, John A.; Duggan, Peter J.; Ecroyd, Heath; Liu, Yanqin; Meyer, Adam G.; and Tranberg, C E.:
Carboxymethylated-k-casein: A convenient tool for the identification of polyphenolic inhibitors of amyloid
fibril formation 2010, 222-228.
https://ro.uow.edu.au/scipapers/949

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Carboxymethylated-k-casein: A convenient tool for the identification of
polyphenolic inhibitors of amyloid fibril formation
Abstract
Reduced and carboxymethylated-κ-casein (RCM-κ-CN) is a milk-derived amyloidogenic protein that
readily undergoes nucleation-dependent aggregation and amyloid fibril formation via a similar pathway to
disease-specific amyloidogenic peptides like amyloid beta (Aβ), which is associated with Alzheimer’s
disease. In this study, a series of flavonoids, many known to be inhibitors of Aβ fibril formation, were
screened for their ability to inhibit RCM-κ-CN fibrilisation, and the results were compared with literature
data on Aβ inhibition. Flavonoids that had a high degree of hydroxylation and molecular planarity gave
good inhibition of RCM-κ-CN fibril formation. IC50 values were between 10- and 200-fold higher with
RCM-κ-CN than literature results for Aβ fibril inhibition, however, with few exceptions, they showed a
similar trend in potency. The convenience and reproducibility of the RCM-κ-CN assay make it an
economic alternative first screen for Aβ inhibitory activity, especially for use with large compound
libraries.
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a b s t r a c t
Reduced and carboxymethylated-j-casein (RCM-j-CN) is a milk-derived amyloidogenic protein that
readily undergoes nucleation-dependent aggregation and amyloid ﬁbril formation via a similar pathway
to disease-speciﬁc amyloidogenic peptides like amyloid beta (Ab), which is associated with Alzheimer’s
disease. In this study, a series of ﬂavonoids, many known to be inhibitors of Ab ﬁbril formation, were
screened for their ability to inhibit RCM-j-CN ﬁbrilisation, and the results were compared with literature
data on Ab inhibition. Flavonoids that had a high degree of hydroxylation and molecular planarity gave
good inhibition of RCM-j-CN ﬁbril formation. IC50 values were between 10- and 200-fold higher with
RCM-j-CN than literature results for Ab ﬁbril inhibition, however, with few exceptions, they showed a
similar trend in potency. The convenience and reproducibility of the RCM-j-CN assay make it an economic alternative ﬁrst screen for Ab inhibitory activity, especially for use with large compound libraries.
Crown Copyright Ó 2009 Published by Elsevier Ltd. All rights reserved.

1. Introduction
Alzheimer’s disease (AD) is a common and debilitating neurodegenerative disorder characterised by gradual loss of cognitive function and behavioural abnormalities.1 One of the pathological
hallmarks of AD is amyloid ﬁbrillar deposits in the brain that consist
mainly of the b-amyloid peptides Ab1–40 and Ab1–42.2 These peptides are proteolytic fragments of the amyloid precursor protein
and are highly hydrophobic and prone to aggregation. Although
Ab is normally present as a random coil, it can form intermediate
oligomers that misfold into ﬁbrils which aggregate to form insoluble amyloid plaques. The mechanism for amyloid formation is postulated to occur through a nucleation-dependent polymerisation.3
Since the formation of Ab ﬁbrillar assemblies is implicated in
AD pathogenesis, food components and therapeutic agents capable
of suppressing or preventing the transition from monomeric to
oligomeric and polymeric Ab species are attractive for the prevention or treatment of AD. Several small molecules have been reported to inhibit the aggregation of Ab, and have been proposed
as therapeutic drug candidates for this disease.4 In relation to this,
there are currently at least two low molecular weight compounds
that target Ab oligomerisation in clinical trials for the treatment of
AD; a synthetic derivative of a natural product isolated from the
* Corresponding author. Tel.: +61 3 9545 2560; fax: +61 3 9545 2446.
E-mail address: peter.duggan@csiro.au (P.J. Duggan).

South American rainforest vine, Uncaria tomentosa,5 and scylloinositol.6
The discovery of novel inhibitors of Ab aggregation is hampered
by the limitations of existing screening methods.7 Typically synthetic Ab peptides are used; however, the preparation of Ab is difﬁcult and costly because it readily aggregates. This propensity to
aggregate can also interfere with the efﬁcacy of a screen because
synthetic Ab often contains oligomeric ‘seeds’ that can nucleate
further aggregation. The use of synthetic Ab in the screening of
large compound libraries thus lacks practicality, and its cost makes
such screening prohibitive for most laboratories. Alternatives need
to be found.
The ability of polypeptide chains to form amyloid ﬁbrils is not
restricted to Ab, but appears to represent a generic feature of
aggregated polypeptide chains.8 These amyloid structures share
common characteristics such as unbranched ﬁbrillar morphology,
cross b-sheet structure and binding of the amyloid-speciﬁc dye thioﬂavin T (ThT). In recent years we have been studying the properties of a derivative of j-casein, a major protein found in bovine
milk, which displays an inherent propensity to rapidly form amyloid ﬁbrils when incubated under conditions of physiological pH
and temperature, with no requirement for denaturants.9 This
derivative of j-casein (denoted as RCM-j-CN) is readily prepared
by reduction of the j-casein disulﬁde linkages and subsequent carboxymethylation. Like Ab ﬁbrils, amyloid ﬁbrils formed from RCMj-CN are cytotoxic.10 Fibril formation by RCM-j-CN can be easily

0968-0896/$ - see front matter Crown Copyright Ó 2009 Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2009.10.063
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monitored using an in situ ThT ﬂuorescence binding assay similar
to that used in assays that study the ﬁbrilisation of Ab.11 The mechanism of such ﬁbril formation by RCM-j-CN has recently been
studied in detail,12 and this protein has shown itself to be a convenient model with which to study generic aspects of ﬁbril
formation.
Flavonoid compounds commonly found in tea and wine have
demonstrated a remarkable propensity to inhibit the formation
and associated toxicity of Ab ﬁbrillar assemblies in vitro. For example, the most abundant polyphenolic extract from green tea, ()epigallocatechin-3-gallate (EGCG, 1, Fig. 1), is one of the most potent inhibitors of amyloid ﬁbril formation of Ab, huntington and asynuclein,13 the amyloidogenic proteins associated with Alzheimer’s, Huntington’s and Parkinson’s diseases, respectively. Very recently we showed that EGCG also efﬁciently inhibits ﬁbril
formation by RCM-j-CN and protects pheochromocytoma-12 cells
from RCM-j-CN amyloid-induced toxicity.10
Given the difﬁculties typically encountered with the screening
of small molecules against synthetic Ab, it was decided that
RCM-j-CN be investigated for its potential to serve as a convenient
initial screen for small molecule Ab anti-ﬁbrilisation activity. Herein are described the results of an investigation of the ability of a set
of common polyphenolics and their derivatives to inhibit ﬁbril formation by RCM-j-CN, as measured by the in situ ThT ﬂuorescence
binding assay. The ﬁndings have been compared with literature Ab
anti-ﬁbrilisation data that were obtained using very similar assay
methods.

ﬂuorescence plate reader. In this study, a small amount of DMSO
(1% v/v) was used to solubilise the test compounds and controls
showed that this amount did not affect the assay. Under the conditions of the assay, the ﬂuorescence of ThT increases in proportion to the amount of ﬁbrillar protein present. After ﬁbril
formation was complete, usually after 1000 min, the intensity of
ﬂuorescence at 490 nm was measured and compared to a control
that lacked the test compound. The difference in ﬁnal ﬂuorescence measured in the control and in the presence of the test
compound was used to calculate % inhibition of ﬁbril formation
(%FFi, Table 1). In cases where the % inhibition was high (usually
80% or higher), a dose–response curve was recorded and from
that, an IC50 value was determined. Only the inhibition of ﬁbril
formation by EGCG (1) with RCM-j-CN has been previously reported. The IC50 value for 1 determined here is lower than that
previously reported10 because the concentration of RCM-j-CN
used in the present study was approximately half of that used
by Hudson et al.10
It is assumed that ThT ﬂuorescence is reduced in the presence of
certain test compounds because these additives disrupt RCM-j-CN
ﬁbril formation. There are, however, a number of other explanations for such an observation which are unrelated to FFi including;
displacement of ThT from the growing ﬁbrils without ﬁbril disruption, interference with ThT ﬂuorescence through physical association of the test compound within the growing ﬁbrils, or light
absorption by the test compound in either the excitation or emission frequencies of ThT.20 To conﬁrm that the compounds that gave
the lowest IC50 values in the ThT assay did actually prevent ﬁbril
formation, transmission electron microscopy (TEM) images were
recorded of a selection of post-assay mixtures (Fig. 4). Such corroborative evidence has already been established with the most active
compound (1).10 Gratifyingly, the micrographs in Figure 4 show a
good correlation between IC50 values and the number of ﬁbrils observed in the TEM images. Where test compounds indicated a
strong inhibition in the ThT assay (IC50 6 14 lM; 6, 8, 11 and 13)
very few ﬁbrils were observed in the corresponding TEM image
compared to the control mixture, which contained 1% DMSO but
no other additive. In addition, the ﬁbrils in these samples were
shorter and/or stunted. Test compounds that gave slightly higher
IC50 values in the ThT assay (7, 9), although allowing much fewer
ﬁbrils to grow than in the control sample, permitted more ﬁbrils
than compounds 6, 8, 11 and 13.

2. Results
Examples of catechins (Fig. 1), ﬂavonols (Fig. 2) and isoﬂavones (Fig. 3) and closely related compounds were chosen for
study because of their well-known abilities to inhibit Ab ﬁbril formation. The speciﬁc examples were selected so that preliminary
structure–activity relationships (SAR) in the inhibition of RCMj-CN ﬁbril formation could be developed. All of the compounds
used in this study are either commercially available, can be readily prepared from commercial starting materials, or in the case of
()-epiafzelechin (4), conveniently isolated from a natural source.
They were assayed using similar methods to those recently described,10 such that the test compounds were incubated with
RCM-j-CN and ThT at physiological pH and temperature in a
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Figure 1. Catechins tested for their ability to inhibit RCM-j-CN ﬁbril formation.
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Figure 2. Flavonols and related compounds tested for their ability to inhibit RCM-j-CN ﬁbril formation.
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Figure 3. Isoﬂavones tested for their ability to inhibit RCM-j-CN ﬁbril formation.

3. Discussion
3.1. SAR in the inhibition of RCM-j-CN ﬁbril formation
A major criterion used to select compounds employed in
this study was their suitability to identify the main SAR relationships in the ﬂavonoid class of compounds in the RCM-j-CN assay. The compounds shown in Figure 1 were chosen so SAR

information around the catechin class of compounds could be
obtained, particularly in relation to the highly active catechin,
EGCG (1). The largest set of closely related compounds examined
was the ﬂavonol group shown in Figure 2 (5–15). These compounds were chosen so that the effect of key structural features
such as hydroxy substitution patterns, methylation and acetylation of the hydroxy groups, and the importance of molecular planarity, on FFi activity could be gauged. The isoﬂavones (Fig. 3)
were chosen because of their close structural similarity with
ﬂavonols.
One of the most active compounds tested was myricetin (8,
IC50 = 8.5 ± 0.7 lM), which is the most highly hydroxylated ﬂavonol in the set. The removal of just one hydroxy group from 8, at
the 50 -position, led to a measureable drop in activity (6,
IC50 = 13.6 ± 3.8 lM) and further deletion of the remaining 30 and 40 -hydroxy groups led to a progressive loss in activity (7,
IC50 = 33.0 ± 2.6 lM; 9, IC50 = 61 ± 44 lM). The removal of the 5hydroxy group on the chromen-4-one ring system again led to a
drop in activity (11, IC50 = 13.9 ± 9.7 lM; 12, no activity—cf. 8
and 7, respectively).
The planarity of these ﬂavonols also appears to be important for
activity: the hydrogenated form of quercetin (6), taxifolin (10,
IC50 = 40.1 ± 3.6 lM) is approximately threefold less active that
quercetin, and molecular modelling Fig. 5) shows marked deviation from planarity in taxifolin relative to quercetin, and also
myricetin. Moving the 30 -hydroxy group on quercetin to the 20 -position to give morin (5), which causes twisting of the phenyl ring
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Table 1
Inhibition of RCM-j-CN ﬁbril formation by test compounds compared with literature values for Ab1–40 and Ab1–42
RCM-j-casein

Compound

a

Ab1–40

Ab1–42

%FFi (single dose)

IC50 ± SEM (lM)

IC50 (lM)

IC50 (lM)

Catechins
1
2
3
4

100
0
7
17

3.7 ± 0.3
—
—
—

0.18b
2.9c
2.8c
—

—h
5.3c
5.6c
—

Flavonols and related compounds
5
6
7
8
9
10
11
12
13
14
15

99i
84
86i
92
68
84i
89i
0
90i
0
35

49.5 ± 16.3
13.6 ± 3.8
33.0 ± 2.6
8.5 ± 0.7
61 ± 44
40.1 ± 3.6
13.9 ± 9.7
—
6.8 ± 1.8
—
—

0.24c
0.24c
1.7c
0.29,c 0.9,d 0.2e
Inactivef
—
—
Enhancerg
—
—
—

0.67c,h
0.72c,h
3.2c
0.40,c 0.34e
—
—h
—

Isoﬂavones
16
17
18
19

95
25i
0
1

190 ± 91
—
—
—

Moderatef
Weakf
—
Inactivef

—h
—
—
—

—
—
—

a
SEM = standard error of mean. FFi = inhibition of ﬁbril formation. Concentrations used in single dose screen: 4; 100 lg/mL: 1–3, 5–7, 9, 10, 13, 15–17; 50 lg/mL: 8; 17 lg/
mL: 14; 12.5 lg/mL: 11, 12, 18, 19; 5 lg/mL.
b
Ref. 14.
c
Ref. 15.
d
Ref. 16.
e
Ref. 17.
f
Ref. 18.
g
Ref. 19.
h
Single dose Ab1–42 % FFi: 1, 5, 6, 10, 16 = 100, 94, 95, 57, 43, respectively.
i
Average of 2–4 determinations.

out of the plane of the chromen-4-one rings (Fig. 5), also reduces
FFi activity (5, IC50 = 49.5 ± 16.3 lM).
The activities of the isoﬂavones (16–19) ranged from low to
undetectable. The most highly hydroxylated isoﬂavone, and the
one with the preferred hydroxylation pattern on the benzene ring
of the chromen-4-one moiety, genistein (16), was the most active
but was still much less active than the majority of ﬂavonols tested.
Of the catechins tested, only EGCG (1) showed measureable FFi
activity with RCM-j-CN. This result supports the SAR associated
with the ﬂavonols; 3,4,5-trihydroxyphenyl moieties appear to have
a strong positive effect on FFi activity. EGCG has two components
of this type and is the most active compound examined in this
study. Removal of the gallate ester and the 50 -hydroxy group to
give ()-epicatechin (3) led to a marked loss in detectable activity.
The set of compounds used in this study can also be used to
gauge the effect of methylation and acetylation of hydroxy groups
on activity: The results obtained with 14, 18 and 19 suggest that
methylation has a strong detrimental effect on FFi activity, with
the clearest example coming from the activity of biochanin A
(18) relative to its unmethylated analogue genistein (16). This simple change, the methylation of a single hydroxy group, led to a
complete loss of detectable FFi activity. The contrast in activities
of related compounds 11 and 14 is stark, and the lack of FFi activity
of 14 presumably results from the combined effects of trimethylation and the presence of a substituent at the 20 -position. More
intriguing is the effect of acetylation. The per-acetylation of quercetin to give 13 actually led to enhanced FFi (IC50 = 6.8 ± 1.8 lM),
with this derivative being second only to EGCG in anti-ﬁbrilisation
activity with RCM-j-CN.
The chalcone (15) was included in the set of test compounds to
determine if a ring-opened form of a polyphenol would show im-

proved activity. This compound is essentially a methylated and
ring-opened form of quercetin (6), and was found to be only
weakly active. Given the apparent correlation between planarity
and FFi activity, this is not surprising. As 15 is highly methylated,
however, and it has already been established that methylation
greatly diminishes FFi activity with RCM-j-CN, little can be concluded about the effect of opening the chromone ring. It can only
be deduced that opening the chromone ring does not compensate
for the detrimental effect of methylation.
Gazit and co-workers have discussed in detail the molecular
mechanisms of the anti-amyloid effects of polyphenols, based on
results obtained with disease-speciﬁc amyloidogenic proteins.14,21
They have suggested that a number of common features of polyphenols make them excellent generic inhibitors of ﬁbril formation,
including their ability to hydrogen bond to the polypeptide back
bone of amyloidogenic proteins through phenolic hydroxy groups,
and to form aromatic p-stacking interactions with the aromatic
amino acid side chains common to the amyloidogenic core of most
amyloid-forming sequences. More recently it has been suggested
that the inhibition of amyloid oligomerisation by polyphenols like
quercetin (6) may be related to the latter’s aggregation properties.22 Bulic et al. have proposed that the ordered self-assembly
demonstrated by many inhibitors of ﬁbril formation may actually
be key to their activity.23 Such assembly of inhibitors would also
involve aromatic p-stacking and hydrogen bonding interactions,
both between the small molecules and between the forming ﬁbrils
and the small molecule assemblies.
The results obtained in the current study suggest that RCM-jCN interacts with polyphenols in a similar way to other amyloidogenic proteins. In particular, a high degree of hydroxylation appears to be important for good FFi with RCM-j-CN, with the
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Figure 4. TEM micrographs of samples taken from completed ThT ﬂuorescence assays. Control contained 1% DMSO but no other additive. Bars represent 1 lm.

most highly hydroxylated compounds in each of the catechin, ﬂavonol and isoﬂavone classes being the most active. In support of
this, methylation leads to a loss of activity. This would imply that
hydrogen bonding to the native-like state of RCM-j-CN, stabilisation of this form and limiting its ﬁbrilisation, is not unique to the

recently characterised interaction with EGCG,10 but is a general
phenomenon with polyphenols. The 3,4,5-trihydroxyphenyl moiety, in particular, appears to be highly beneﬁcial to FFi activity.
The result obtained with quercetin pentaacetate (13) is surprising as this compound can only act as a hydrogen bond acceptor, not
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CN IC50 values cannot be directly correlated with those obtained
with either Ab1–40 or Ab1–42, the assay’s ease of operation, reproducibility and robustness under physiological conditions makes it
a very useful and economic ﬁrst screen for FFi activity, especially
when large compound sets are being considered.
4. Conclusions

Figure 5. Energy minimised structures (MM2; Chem3D Pro 11.0) of quercetin (6),
myricetin (8), (+)-taxifolin (10) and morin (5) viewed from C-6.

as a donor. One of the major challenges to the application of polyphenols for the treatment of neurodegenerative diseases is the
penetration of the blood–brain-barrier (BBB). The BBB penetration
of highly polar compounds like polyphenols is expected to be very
limited,24 but the result obtained with 13 suggests that acylation
may be a way of improving BBB penetration of polyphenols without greatly diminishing their anti-ﬁbrilisation activities. This result
deserves further investigation.
The beneﬁcial effect of planarity in the test compounds on FFi,
as demonstrated by the activity of quercetin (6) relative to taxifolin
(10) and morin (5), supports the notion that aromatic p-stacking
interactions, as with other amyloidogenic proteins,14,20 are important in the prevention of the ﬁbrilisation of RCM-j-CN, as it is expected that deviation from the plane would greatly disrupt such
associations.
3.2. Comparisons with inhibition of Ab1–40 and Ab1–42 ﬁbril
formation
Literature ThT FFi results with either Ab1–40 or Ab1–42 are available for more than half of the compounds examined in this study,
and these results are listed in Table 1. Where quantitative data are
available (compounds 1, 5–9), the polyphenols studied are between 20- and 200-fold less active in the RCM-j-CN ThT assay
than in the Ab1–40 ThT assay, and between 10- and 74-fold less active than in the Ab1–42 assay. With the exception of morin (5) however, the order of activity is in general agreement between the
assays: RCM-j-CN; 1 > 8 > 6 > 7 > 5 > 9, Ab1–40; 1 > 5  6 > 8 > 7
> 9, Ab1–42; 8 > 5 > 6 > 7. Qualitative Ab1–40 data are available for
another ﬁve compounds (9, 12, 16, 17 and 19) and with the exception of galangin (9), the trend in activity is again in general agreement: RCM-j-CN; 9 > 16 > 17 > 19 = 12, Ab1–40; 16 > 17 > 9 = 19
> 12. As a further comparison, we determined the %FFi with Ab1–
42 by a sub-set of compounds; 1, 5, 6, 10 and 16 (Table 1, footnote
h) and the results again showed a similar trend in FFi activity to
those obtained with RCM-j-CN.
The RCM-j-CN ThT assay described here appears to be a good
predictor of anti-ﬁbrilisation activity with Ab, and while RCM-j-

We have employed a series of ﬂavonoids, a number of which are
known to be active in Ab ﬁbrilisation assays, to test their ability to
inhibit RCM-j-CN ﬁbril formation, in order to study the structure–
activity relationships around the inhibition of RCM-j-CN ﬁbril formation and to determine if this j-casein derivative can be used in a
convenient and economic ﬁrst screen for anti-ﬁbrilisation activity
of small molecules with Ab.
A number of structural features of these ﬂavonoids that have
already been identiﬁed to be important in the inhibition of ﬁbrilisation of disease-speciﬁc peptides like Ab were also found to
favour the inhibition of ﬁbrilisation of RCM-j-CN. These include
a high degree of hydroxylation, which is thought to encourage
the association of the test compound through hydrogen bonding
with the polyamide backbone of the native-like state of RCM-jCN, thus stabilising this form and limiting its ﬁbrilisation. The
3,4,5-trihydroxyphenyl substituent appears to be highly beneﬁcial
in this regard, with the most active compound tested, EGCG (1)
possessing two such substituents. Consistent with these ﬁndings,
the exchange of phenol substituents to methyl ethers has a marked
negative effect on the inhibition of ﬁbrilisation. Surprisingly the
acetyled form of quercetin (6) led to an improvement in activity,
which suggests possibilities for the promotion of BBB penetration
while maintaining anti-ﬁbrilisation activity. Co-planarity of aromatic moieties also appears to be beneﬁcial, with structural features that cause deviation from the plane being associated with a
drop in activity. This supports the notion that p-stacking interactions of the test compounds with the aromatic amino acid side
chains in the amyloidogenic core of RCM-j-CN, and/or in the
self-assembly of the test compounds, also limits ﬁbrilisation.
The polyphenols studied are between 20- and 200-fold less active in the RCM-j-CN assay than in the Ab1–40 assay, and between
10- and 74-fold less active than in the Ab1–42 assay. This may be
attributable to a number of factors which could be related to differences between RCM-j-CN and Ab in size, hydrophobicity, structure
of the native state and the kinetics of ﬁbril formation. With only a
few exceptions, however, the order of potency of these polyphenols is in agreement for both types of protein. The RCM-j-CN assay
described here thus appears to be a good predictor of anti-ﬁbrilisation activity with Ab, and the assay’s convenience and reproducibility makes it a valuable ﬁrst screen for FFi activity, especially
with large compound libraries.

5. Experimental
5.1. Materials

j-Casein obtained from Sigma–Aldrich Chemical Co. (St. Louis,
MO, USA) was reduced and carboxymethylated as described by
Shechter et al.25 and the lyophilised product was stored at
20 °C until use. Fresh solutions of RCM-j-CN were prepared each
day and discarded after use. Compounds 1–3, 5–10 and 16–18 are
available from Sigma–Aldrich; compounds 11 and 12 are available
from Indoﬁne Chemical Co. (Somerville, NJ, USA); compound 13 is
available from Maybridge via Fisher Scientiﬁc (Loughborough,
Leicestershire, UK); compound 19 is available from AvaChem Scientiﬁc (San Antonio, TX, USA). ()-Epiafzelechin (4) can be readily
isolated from the heartwood of afzelia species,26 compound 14 can
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be prepared from 6,7,70 -trimethoxychromono(30 ,20 ,4)isocoumarin27 by reduction with sodium borohydride28 and compound 15
can be prepared by basic hydrolysis of pentamethyl taxifolin.29

MilliQ water). Grids were dried with clean ﬁlter paper between
each of these steps. After being left to air dry, the samples were
viewed at 19,000 magniﬁcation using a Philips CM100 transmission electron microscope (Philips, Eindhoven, The Netherlands).

5.2. Thioﬂavin T assay
The formation of amyloid ﬁbrils by RCM-j-CN was monitored
using an in situ ThT binding assay.12 A stock solution of RCM-jCN (1.0 mg/mL or 52 lM) was prepared in 100 mM sodium phosphate buffer (pH 7.2), centrifuged and ﬁltered (0.22 lm) and then
kept on ice before being aliquoted into the wells of a 96-well plate
(see below). The test compounds were ﬁrst dissolved in a small
amount of DMSO and then diluted in MilliQ water such that their
ﬁnal concentration ranged from 10 to 200 lg/mL, depending on
their solubility in DMSO. Preliminary assays showed that ﬁbril formation by RCM-j-CN is sensitive to the presence of DMSO and
therefore the ﬁnal DMSO concentration did not exceed 1%, which
was not found to signiﬁcantly affect ﬁbril formation. Both the
RCM-j-CN and test compounds were then diluted twofold into
black lClear 96-microwell plates (Greiner Bio-One, Stonehouse,
UK) such that the ﬁnal concentrations were 0.5 mg/mL
(RCM-j-CN), 5–100 lg/mL for the test compounds and the phosphate buffer concentration was 50 mM (pH 7.2) in a total volume
of 200 lL. ThT from a stock solution made up in phosphate buffer
(50 mM, pH 7.2) was added to give a ﬁnal concentration of 10 lM.
The plates were sealed (thin seal self-adhesive plate covers, Excel
Scientiﬁc, Chicago, IL, USA) to prevent evaporation and incubated
at 37 °C without shaking. The time between when the lyophilised
RCM-j-CN was ﬁrst dissolved in buffer and when the stock solution was diluted into the plate and the assay commenced was
approximately 1 h. The ﬂuorescence intensity of each well was recorded every 5 min for 1000 min using a Fluostar Optima plate
reader (BMG Labtechnologies, Melbourne, Australia) with a 440/
490 nm excitation/emission ﬁlter. All samples were prepared in
duplicate. The percent inhibition of ﬁbril formation (FFi%) was calculated from the change in ThT ﬂuorescence in the absence and
presence of the compounds as follows: %FFi = 100  (DFc  DFs)/
DFc, where DFc and DFs represent the change in ThT ﬂuorescence
in the absence (control) and the presence of test compound,
respectively. For those compounds that gave a high %FFi (i.e., usually 80% or higher), a dose–response study was performed over
four different concentrations of test compound and an IC50 value
was determined using GraphPad PRISM 5.01 (GraphPad Software,
San Diego, CA, USA). EGCG (1) was included as a positive control
in each batch of test compounds. The four individual IC50 values
thus determined for this compound were in close agreement and
the value shown in Table 1 is an average of these four numbers.
5.3. Transmission electron microscopy
Samples for TEM were prepared by taking 5 lL of each sample
directly from the ThT assay and applying it to a carbon-coated
400-mesh nickel TEM grid (ProSciTech, Australia). The grid was
then washed with 0.22 lm ﬁltered MilliQ water (3  10 lL) and
negatively stained with uranyl acetate solution (5 lL, 2% w/v, in
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